Silver Book Fact

Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.

Wagner, Edward, Nirmala Sandhu, Katherine Newton, David McCulloch, Scott Ramsey, and Louis Grothaus. Effect of Improved Glycemic Control on Health Care Costs and Utilization. JAMA. 2001; 285(2): 182-189. http://jama.ama-assn.org/cgi/content/abstract/285/2/182

Reference

Title
Effect of Improved Glycemic Control on Health Care Costs and Utilization
Publication
JAMA
Publisher
JAMA
Publication Date
2001
Authors
Wagner, Edward, Nirmala Sandhu, Katherine Newton, David McCulloch, Scott Ramsey, and Louis Grothaus
Volume & Issue
Volume 285, Issue 2
Pages
182-189
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…  
  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.